Clinical trial · Observational
Study of Prediction of Ovarian Reserve in Yong Breast Cancer Patients Treated With Chemotherapy
International Peace Maternity and Child Health Hospital (IPMCH) Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai, China
NCT04767607CI-TRIAL-00074725completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to predict the ovarian reserve, especially premature ovarian insufficient (POI), in young breast cancer patients during chemotherapy treatment using ultrasensitive anti-Müllerian hormone (AMH) detection method.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Breast cancer plus chemotherapy
- description
- Patients of the group will receive chemotherapy treatment.
- label
- Breast cancer without chemotherapy
- description
- Patients of the group will not receive chemotherapy treatment.
Primary outcomes (1)
- measure
- To evaluate the trend of anti-Müllerian hormone (AMH) level at chemotherapy process and post-chemotherapy in breast cancer patients.
- timeFrame
- 1 year.
- description
- Serum anti-Müllerian hormone (AMH) concentration can be measured on any day during the menstrual cycle. Serum AMH will be measured at each chemotherapy administration and 1 year post-chemotherapy.
Secondary outcomes (1)
- measure
- To evaluate the trend of Follicle-Stimulating Hormone (FSH) level at chemotherapy process and post-chemotherapy in breast cancer patients.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: 1. Female 18-50 years. 2. Suffering from breast cancer. 3. Treated with adjuvant or neoadjuvant chemotherapy. 4. Having regular menstrual cycle before chemotherapy. Exclusion Criteria: 1. Bilateral oophorectomy or ovarian irradiation before enrollment. 2. Prior chemotherapy. 3. Oral contraceptives before enrollment. 4. Pregnancy or lactation.
References
Publications (4)
- BACKGROUNDDezellus A, Barriere P, Campone M, Lemanski C, Vanlemmens L, Mignot L, Delozier T, Levy C, Bendavid C, Debled M, Bachelot T, Jouannaud C, Loustalot C, Mouret-Reynier MA, Gallais-Umbert A, Masson D, Freour T. Prospective evaluation of serum anti-Mullerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. Eur J Cancer. 2017 Jul;79:72-80. doi: 10.1016/j.ejca.2017.03.035. Epub 2017 Apr 29. PMID 28463758
- BACKGROUNDFreour T, Barriere P, Masson D. Anti-mullerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy. Eur J Cancer. 2017 Mar;74:1-8. doi: 10.1016/j.ejca.2016.12.008. Epub 2017 Jan 28. PMID 28135602
- BACKGROUNDLie Fong S, Lugtenburg PJ, Schipper I, Themmen AP, de Jong FH, Sonneveld P, Laven JS. Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod. 2008 Mar;23(3):674-8. doi: 10.1093/humrep/dem392. Epub 2008 Jan 23. PMID 18216040
- DERIVEDKuang X, Ji M, Tang Y, Wang Q, Pan S, He J, Anderson RA, Wang BS, Xu H, Lai D. Monitoring ovarian reserve dynamics via a high-sensitivity anti-Mullerian hormone assay in premenopausal breast cancer patients undergoing chemotherapy. Hum Reprod. 2026 Aug 28:deag136. doi: 10.1093/humrep/deag136. Online ahead of print. PMID 42664366